S9 Ep7: Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis
OncLive® On Air - Un pódcast de OncLive® On Air
Dr Kremyanskaya discusses the results from cohort 1 of the MANIFEST trial in treatment-naïve myelofibrosis, differentiating features of pelabresib and recently approved JAK inhibitors, and next steps for the investigation of BET inhibitors in this population.
